ArticleMolecular cancer research : MCR2015
Annexin 2-CXCL12 interactions regulate metastatic cell targeting and growth in the bone marrow.
Article in Molecular cancer research : MCR, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 29 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
29 citing papers in PubMed, 42 citations in OpenAlex.
- Review
- Estrogenic prevention of luteinizing hormone releasing hormone agonist-induced bone loss.The Journal of endocrinology · 2025Article
- Annexin A2: the feasibility of being a therapeutic target associated with cancer metastasis and drug resistance in cancer microenvironment.Discover oncology · 2024Review
- Role of Chemokines and Cytokines in Prostate Cancer Skeletal Metastasis.Current osteoporosis reports · 2024Review
- Mendelian randomization identifies circulating proteins as biomarkers for age at menarche and age at natural menopause.Communications biology · 2024Article
- Review
- Prostate cancer and bone: clinical presentation and molecular mechanisms.Endocrine-related cancer · 2023Review
- Review
- Role of myeloid-derived suppressor cells in tumor recurrence.Cancer metastasis reviews · 2023Review
- Review
- The multifaceted roles of the chemokines CCL2 and CXCL12 in osteophilic metastatic cancers.Cancer metastasis reviews · 2021Review
- Annexin Animal Models-From Fundamental Principles to Translational Research.International journal of molecular sciences · 2021Review
- Adrenergic Blockade Promotes Maintenance of Dormancy in Prostate Cancer Through Upregulation of GAS6.Translational oncology · 2020Article
- Cytokines and Chemokines as Mediators of Prostate Cancer Metastasis.International journal of molecular sciences · 2020Review
- Switching Homes: How Cancer Moves to Bone.International journal of molecular sciences · 2020Review
- Bone microenvironment signaling of cancer stem cells as a therapeutic target in metastatic prostate cancer.Cell biology and toxicology · 2020Review
- Metastatic Spread in Prostate Cancer Patients Influencing Radiotherapy Response.Frontiers in oncology · 2020Review
- Crucial role of Anxa2 in cancer progression: highlights on its novel regulatory mechanism.Cancer biology & medicine · 2019Article
- Parallels between hematopoietic stem cell and prostate cancer disseminated tumor cell regulation.Bone · 2019Review
- Genetics and biology of prostate cancer.Genes & development · 2018Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 1 institution in 1 country.
Funding
Abstract
unlabelledAnnexin 2 (ANXA2) plays a critical role in hematopoietic stem cell (HSC) localization to the marrow niche. In part, ANXA2 supports HSCs by serving as an anchor for stromal-derived factor-1 (CXCL12/SDF-1). Recently, it was demonstrated that prostate cancer cells, like HSCs, use ANXA2 to establish metastases in marrow. The present study determined the capacity of ANXA2 expression by bone marrow stromal cells (BMSC) to facilitate tumor recruitment and growth through ANXA2-CXCL12 interactions. Significantly more CXCL12 was expressed by BMSC(Anxa2) (+/+) than by BMSC(Anxa2) (-/-) resulting in more prostate cancer cells migrating and binding to BMSC(Anxa2) (+/+) than BMSC(Anxa2) (-/-), and these activities were reduced when CXCL12 interactions were blocked. To further confirm that BMSC signaling through ANXA2-CXCL12 plays a critical role in tumor growth, immunocompromised SCID mice were subcutaneously implanted with human prostate cancer cells mixed with BMSC(Anxa2) (+/+) or BMSC(Anxa2) (-/-). Significantly larger tumors grew in the mice when the tumors were established with BMSC(Anxa2) (+/+) compared with the tumors established with BMSC(Anxa2) (-/-). In addition, fewer prostate cancer cells underwent apoptosis when cocultured with BMSC(Anxa2) (+/+) compared with BMSC(Anxa2) (-/-), and similar results were obtained in tumors grown in vivo. Finally, significantly more vascular structures were observed in the tumors established with the BMSC(Anxa2) (+/+) compared with the tumors established with BMSC(Anxa2) (-/-). Thus, ANXA2-CXCL12 interactions play a crucial role in the recruitment, growth, and survival of prostate cancer cells in the marrow. IMPLICATIONS: The tumor microenvironment interaction between ANXA2-CXCL12 is critical for metastatic phenotypes and may impact chemotherapeutic potential.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.